Latest Insights on SES

The latest U.S. private payrolls data are in, and the economy is looking stronger than ever! (If you judge things solely on jobs data, that is.) Jobs Wow Wall Street … Disney, Not so Much February 5, 2020 by Joseph Hargett Great Stuff Keepin’ the Bulls Happy I live for moments like today, dear reader. The latest U.S. private payrolls data are in, and the economy is looking stronger than ever! (If you judge things solely on jobs data, that is.) Yes, I know I preach a bit of doom and gloom from time to time, but someone […]
Today, I want to talk about a few of the most popular investing tools … as well as a brand-new investment strategy that I believe deserves your attention. It’s Time to Upgrade Your Investing Toolbox February 5, 2020 by Brian Christopher Investing, Trading Strategies, Winning Investor Daily Today, I want to talk about a few of the most popular investing tools … as well as a brand-new investment strategy that I believe deserves your attention.
If you don’t think the Wuhan coronavirus outbreak will impact the U.S. economy, I’ve got some bad news for you. The Chinese Time Bomb; Tesla Tendies Time February 4, 2020 by Joseph Hargett Great Stuff The Ticking Chinese Time Bomb Sorry to ruin your bull market party, but there’s an issue we need to discuss … like, right now. I’m talking about the Wuhan coronavirus and the U.S.-China “phase 1” trade deal. Here’s the thing: More than 20,000 Chinese are infected with the Wuhan virus, with some 427 dead. Tens […]
Billionaire Ken Griffin’s strategy is an example of how to grow wealth fast. It’s how he made his $13 billion fortune. Invest Like a Billionaire With 1 Simple Trick February 4, 2020 by Michael Carr Investing, Trading Strategies, Winning Investor Daily Billionaire Ken Griffin’s strategy is an example of how to grow wealth fast. It’s how he made his $13 billion fortune.
abbvie stock Profit From AbbVie’s Struggles Today February 4, 2020 by Chad Shoop American Investor Today, Stocks Abbvie’s flagship medication Humira is a huge seller in the U.S. and abroad. But as more companies develop their own versions, will Abbvie’s stock crater in the face of tighter competition? I’ll review Abbvie’s balance sheet and fundamentals to let you know whether you should expect the stock to surge — or fall even further in 2020.

Newsletter Sign Up

Sponsored

CS Care Video

MEET OUR EXPERTS

WHAT READERS ARE SAYING..

“My portfolio has grown from 275k to almost 900k with only investments made with Banyan Hill.”

- David G. (Member since 2018)

"I couldn’t believe it … in just 2 months, I made $298,506 on one stock – that’s a 24% gain!"

- John B.

“I started with $215,000 in Nov. 2018, It is now over 800,000. So very happy with Banyan Hill Publishing.”

- Larry K.

Share This